The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe to give nevirapine (NVP) to breast-feeding
babies from birth to the age of 6 months and to determine what dose of NVP should be given.
Breast-feeding has been shown to be very important for the physical and mental health of
infants. This is especially true during the first 6 months of life. However, an HIV-positive
mother can pass the virus on to her baby by breast-feeding. Because of this risk,
HIV-positive mothers are encouraged to formula-feed, not breast-feed, their babies. In
developing countries, however, some women cannot afford to formula-feed. If they do
formula-feed, these women risk exposing their HIV status. These women have great need for
methods that can lower the chance that they will pass HIV on to their babies. This study will
test NVP as a way of doing this.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)